Use of mycophenolic acid in non-transplant renal diseases

Nephrology Dialysis Transplantation

Volumn 22, Issue 4, 2007, Pages 1013-1019

  Stassen, Patricia M ^a   Kallenberg, Cees G M ^b   Stegeman, Coen A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Enteric coated mycophenolate sodium; Mycophenolate mofetil; Mycophenolic acid; Renal disease; Review; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; STEROID;

ABDOMINAL PAIN; ANCA ASSOCIATED VASCULITIS; ANEMIA; AORTA ARCH SYNDROME; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; GOODPASTURE SYNDROME; HEMATOLOGIC DISEASE; HEMATURIA; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; PATIENT SELECTION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; REMISSION; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; NEPHROSIS, LIPOID; VASCULITIS;

EID: 34047199798     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl844     Document Type: Review

References (50)

1. Sollinger HW. Mycophenolates in transplantation. Clin Transpl 2004; 18: 485-492
2. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 [Suppl 1]: S2-s8
3. Eugui EM. Fibrogenesis in chronic allograft rejection: Underlying mechanisms and pharmacological control. Transplant Proc 2002; 34: 2867-2871
4. MacPhee IA, Spreafico S, Bewick M et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000; 57: 1164-1168
5. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
6. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
7. Hu W, Liu Z, Chen H et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002; 115: 705-709
8. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-510
9. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
10. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
11. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-539
12. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432
13. Pasquali S, Banfi G, Zucchelli A et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39: 175-182
14. Spetie DN, Tang Y, Rovin BH et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66: 2411-2415
15. Karim MY, Pisoni CN, Ferro L et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology 2005; 44: 1317-1321
16. Borba EF, Guedes LK, Christmann RB et al. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 2006; 26: 1078-1083
17. Kasitanon N, Fine DM, Haas M et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate therapy for membranous lupus nephritis. Lupus 2006; 15: 366-370
18. Strippoli GF, Manno C, Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: Assessment and criticism. Am J Kidney Dis 2003; 41: 1129-1139
19. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774
20. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114
21. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849
22. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145
23. Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802-812
24. Dal Canton A, Amore A, Barbano G et al. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: A multicenter, randomised, controlled study. J Nephrol 2005; 18: 136-140
25. Miller G, Zimmerman R,III, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250-256
26. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003; 18: 1233-1234
27. du Buf-Vereijken PW, Wetzels JF. Mycophenolate mofetil (MMF) versus cyclophosphamide (CP) in patients with idiopathic membranous nephropathy (MN) and renal insufficiency (Abstract). J Am Soc Nephrol 2004; 14: A341
28. Briggs WA, Choi MJ, Scheel PJ,Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-217
29. Mogyorosi A, Lippman HR, Feldman GM. Successful treatment of steroid-resistant minimal change disease with mycophenolate mofetil. Am J Nephrol 2002; 22: 569-572
30. Day CJ, Cockwell P, Lipkin GW et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17: 2011-2013
31. Zhao M, Chen X, Chen Y et al. Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology 2003; 8: 105-109
32. Pesavento TE, Bay WH, Agarwal G, Hernandez RA,Jr, Hebert LA. Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy. Am J Kidney Dis 2004; 43: E3-e6
33. Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 2003; 42: 1114-1120
34. Mendizabal S, Zamora I, Berbel O et al. Mycophenolate mofetil in steroid/ cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20: 914-919
35. Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: Current status and future directions. Pediatr Nephrol 2005; 20: 1376-1381
36. Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62: 405-411
37. Preddie DC, Nickolas TI, Schwimmer J et al. Use of mycophenolate mofetil in steroid intolerant or refractory acute interstitial nephritis (Abstract). J Am Soc Nephrol 2004; 15: FPO250
38. Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 2006; 21: 281-285
39. Jones G, Juszczak M, Kingdon E et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004; 19: 3160-3164
40. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-2732
41. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2005; 102: C100-c107
42. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil (Abstract). Kidney Blood Press Res 2003; 26: 292(030)
43. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283
44. Haidinger M, Neumann I, Grutzmacher H et al. Mycophenolate mofetil (MMF) treatment of ANCA-associated small-vessel vasculitis: A pharmocokinetically controlled study (Abstract). Clin Exp Immunol 2000; 120 [Suppl 1]: S72
45. Nowack R, Gobel U, Klooker P et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971
46. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases. Ann Intern Med 1999; 130: 422-426
47. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br. J. Dermatol 2000; 143: 1324
48. Garcia-Canton C, Toledo A, Palomar R et al. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant 2000; 15: 920-922
49. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 645-663
50. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17: 962-971